Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis.

Date publication

janvier 2016

Journal

Angiogenesis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MULLER Sylviane

Tous les auteurs :
Semerano L, Duvallet E, Belmellat N, Marival N, Schall N, Monteil M, Grouard-Vogel G, Bernier E, Lecouvey M, Hlawaty H, Muller S, Boissier MC, Assier E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26419779

Résumé

Inflammation and angiogenesis are two tightly linked processes in arthritis, and therapeutic targeting of pro-angiogenic factors may contribute to control joint inflammation and synovitis progression. In this work, we explored whether vaccination against vascular endothelial growth factor (VEGF) ameliorates collagen-induced arthritis (CIA).

Mots clés

Amino Acid Sequence, Animals, Antibody Formation, immunology, Arthritis, Experimental, immunology, Human Umbilical Vein Endothelial Cells, Humans, Immunity, Humoral, immunology, Immunization, Inflammation, pathology, Joints, pathology, Male, Mice, Molecular Sequence Data, Molecular Targeted Therapy, Peptides, chemistry, Synovial Membrane, blood supply, Vaccines, immunology, Vascular Endothelial Growth Factor A, chemistry

Référence

Angiogenesis. 2016 Jan;19(1):39-52